What does the evidence say about Vitamin K2 Cardiovascular Markers Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K2 Cardiovascular Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 Chronic kidney disease (CKD) is a global health burden characterized by progressive deterioration of kidney function and increased morbidity and mortality. [Chen Chengbo (2026); evidence level 4] - CAC, defined as the deposition of calcium in coronary arteries, is a key indicator of atherosclerotic disease and strongly correlates with cardiovascular events, particularly in CKD patients who are at higher risk due to their disrupted mineral metabolism [,]. [Chen Chengbo (2026); evidence level 4] - Conversely, vitamin K2 is a critical cofactor for the activation of matrix Gla-protein (MGP), a potent inhibitor of vascular calcification, and deficiencies in vitamin K2 are associated with increased vascular calcification and cardiovascular events [,,,]. [Chen Chengbo (2026); evidence level 4] - Among its various complications, cardiovascular disease remains the leading cause of death in CKD patients, with coronary artery calcification (CAC) playing a pivotal role in cardiovascular pathology [,]. [Chen Chengbo (2026); evidence level 4] - Background/Objectives : Post-menopausal women are at an increased risk of developing cardiovascular disease. [de Vries F (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.